ULTOMIRIS (ravulizumab-cwvz) is the first and only long-acting C5 complement inhibitor that offers patients with aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (N...
Sanofi is presently engaged in the exploration of Riliprubart (SAR445088), a monoclonal antibody designed to selectively target the serine protease C1s, in pursuit of its potential therapeutic application in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Riliprubart unveils compelling efficacy in CID...
Find More
ULTOMIRIS (ravulizumab-cwvz) is the first and only long-acting C5 complement inhibitor that offers patients with aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) the potential to live relapse-free. The remarkable reduction in relapse risk observed in the CHAMPION-NMOSD t...
Find More
Takeda and Ovid Therapeutics with soticlestat, a first-in-class cholesterol 24-hydroxylase inhibitor, holds promise for transformative therapy marking a milestone in advancing treatment options for individuals with refractory epilepsies associated with Dravet syndrome and Lennox-Gastaut syndrome. Soticles...
Find More
Cenobamate, marketed as XCOPRI in the US and ONTOZRY in the EU, provides various dosage choices to improve treatment adherence and efficacy. SK Life Science’s cenobamate via its multimodal approach, provides much-needed relief for patients with partial-onset seizures by reducing repetitive neuronal firing...
Find More
Athira Pharma presented a poster titled “Targeting Neurotrophic HGF Signaling for the Treatment of Neurodegenerative Disorders” at the recently, concluded American Academy of Neurology 2024 Annual Meeting, held in Denver, Colorado. It highlighted preclinical data supporting the development of Athira's pipeline of s...
Find More
Semaglutide provides a potential therapeutic avenue for aging-related neurodegenerative diseases, such as Alzheimer's disease through enhanced brain glucose metabolism. The comparable safety data presented by Novo Nordisk strengthens Semaglutide’s profile as a potential candidate in the early Alzheimer’s Diseas...
Find More
PRX012, a next-generation subcutaneous antibody, has the potential to eliminate treatment obstacles due to its unique pharmacological properties and improved binding profile compared to conventional amyloid-beta targeting medicines. PRX123, targeting the hallmarks of Alzheimer’s, Aβ plaque, and tau tangles, has...
Find More
Donanemab, with improved safety, efficacy, convenient dosing regime, and most importantly its ability to not only prevent but also clear plaques has the potential to redefine the treatment regime for Alzheimer’s patients. With a comparable safety profile, Eli Lilly delivers on even the most basic outcomes essen...
Find More
Ipsen Partners with Skyhawk Therapeutics for RNA-Focused Research in Rare Neurological Disorders Ipsen and Skyhawk Therapeutics have entered into an exclusive global partnership to explore and create new small molecules that can influence RNA for rare neurological conditions. Under this agreement, Ipsen has the ...
Find More
Myasthenia Gravis is a chronic autoimmune neuromuscular disease responsible for weakness in the skel.....
Find More
Major Depressive Disorder (MDD), also known as clinical depression, is a severe, debilitating and fr.....
Find More
An autosomal recessive disorder, Ataxia Telangiectasia, affects a person's nervous system, immune sy.....
Find More
Gene therapies are regarded as one of the potential revolution in the Pharmaceutical field and Healt.....
Find More
Doctors and scientists have recognized that traditional, complementary and alternative therapies hav.....
Find More
Digital health technologies can fill the current gaps in oncology care while rebalancing the existin.....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
